Navigation Links
Takeda Receives New Information on Alogliptin (SYR-322) NDA
Date:3/6/2009

OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA's December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.

Additionally, the FDA does not believe that the amount of existing alogliptin clinical data is sufficient to meet certain statistical requirements in the new guidance. The agency is open to discussions regarding the design of additional CV studies with alogliptin. Alogliptin's Prescription Drug User Fee Act (PDUFA) date - June 26, 2009 - remains unchanged.

In December, 2008 the FDA issued "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes".

In October 2008, Takeda received notification from the FDA that it was unable to complete its review of the alogliptin NDA by the original PDUFA date -- October 27, 2008 -- due to internal resource constraints. The FDA did not raise any issues with the data in the alogliptin NDA at that time. In December 2007, Takeda submitted its NDA for alogliptin to the FDA.

Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.

About DPP-4 Inhibitors

DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase IV (DPP-4), which metabolizes the insulin-increasing hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
2. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
3. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
4. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
5. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
6. Takeda Completes Acquisition of Millennium
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. Takeda Announces New U.S. Leadership
10. Takeda submits new drug application for alogliptin (syr-322) in the US
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 Teams ... lean manufacturing improvements use the new Do-Done StepTracker whiteboard ... “We use the Do-Done board to display the current ... of our production cells and departments is listed down ... As we start a project, the squares are filled ...
(Date:5/22/2013)... Purchase, NY (PRWEB) May 22, 2013 ... formed an exclusive partnership with Aurora Financial Systems, ... marketing tool to companies that offer Medicare Advantage ... rewards members for completing 3 out of 12 ... incentive product launched March 2013, and provides an ...
(Date:5/22/2013)... Montgomery, Alabama (PRWEB) May 22, 2013 ... technology solutions to state Health and Human Services ... Department of Mental Health (ADMH) selected the ... state-wide platform to manage the Health Records and ... state-operated psychiatric hospitals. , CoCENTRIX is transitioning ...
(Date:5/22/2013)... NJ (PRWEB) May 22, 2013 ... and management solutions for social enterprise collaboration platforms, ... a consulting firm based in Chicago, Ill. The ... their products and provide best-in-class solutions for SharePoint ... improve collaboration. , AvePoint’s DocAve Software Platform ...
(Date:5/22/2013)... 22, 2013 Patients with type 1 ... have better glycemic control as measured by significantly lower ... condition with insulin injections, according to new findings from ... conducted by Kantar Health . The research was ... (International Society for Pharmacoeconomics and Outcomes Research) in New ...
Breaking Medicine News(10 mins):Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Integrated Printing Solutions and Aurora Financial Systems, Inc. Create Partnership for Healthcare Incentive Card 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 2Health News:AvePoint Teams with Tahoe Partners, LLC to Enrich Microsoft SharePoint Deployments and Improve Collaboration 3Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 2Health News:Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research 3
... ... the latest technologies in Refractive and Corneal Surgery. , ... (Vocus) March 30, 2010 -- The Khanna Institute opens new office ... cities in the world. The city is known for its famous zip code, phenomenal shopping ...
... for this common condition, researchers say , TUESDAY, March 30 ... known as deep vein thrombosis, it is most likely to ... leg, Canadian researchers have found. , Dr. Wee-Shian Chan ... newly published review, said in a news release that the ...
... Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs ... symptoms of arthritis and other inflammatory disorders. But ... have osteoarthritis) these medications are also known to ... body, particularly in the gastrointestinal tract. ...
... that point to spectrum disorders , TUESDAY, March 30 ... brain proteins that seem to be linked to autism ... the most comprehensive genetic analyses of association between these ... disorder] risk," said Anthony Monaco, of the Wellcome Trust ...
... dying rose among older people cared for in minority ... many supportive relatives actually increases the fear of dying ... researchers. , The finding runs counter to the common ... the fear of death. It also has important implications ...
... has been thought that the loss of physical and psychological ... in brain structures. However, in the current edition of ... 107[12]: 199-205), Rainer Scheid and D. Yves von Cramon conclude ... brain injury is more frequent than stroke and is mostly ...
Cached Medicine News:Health News:The Khanna Institute of LASIK and Refractive Surgery Opens New Office in Beverly Hills 2Health News:McMaster researcher leads development of promising drug for inflammation 2Health News:More Family Support Can Raise Fears For Some Elderly 2
(Date:5/22/2013)... May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces addition ... Guidebook Series (4) 2013 Edition Material and Clinical ... Drug Registration: A Guidebook of Registration Application for ... to its online database. The traditional ... are always regarded by occidental as mysterious medicines. ...
(Date:5/22/2013)... VANCOUVER, British Columbia , May 22, 2013  OncoGenex ... the development of novel therapeutics to target mechanisms of treatment ... investigational compounds, custirsen and OGX-427, will be presented as "Trials ... of the American Society of Clinical Oncology (ASCO) in ... 4. Despite the availability of drugs that ...
(Date:5/21/2013)... 2013 Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and operator ... centers in China and the parent of Chang,an Hospital, ... first quarter ended March 31, 2013 [1] . ... revenue, which consists of net revenues generated from the ...
Breaking Medicine Technology:China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13
... 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ) ... Conference being held May 2 to 4, 2011 at the ... Merrill Lynch Healthcare Conference being held May 10 to 12, ... Price, Pharmasset,s President and Chief Executive Officer, will provide an ...
... 28, 2011 The U.S. Food and Drug ... with prednisone (a steroid) to treat patients with ... prior docetaxel (chemotherapy). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... sex hormone testosterone stimulates prostate tumors to grow. ...
Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: